Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be ...
Dealbreaker on MSN
Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds
Tourmaline licensed the atherosclerotic cardiovascular disease drug pacibekitug from Pfizer, which remains eligible for ...
Novartis is paying $1.4 billion to get its hands on Tourmaline Bio and its former Pfizer cardiovascular drug that impressed ...
Tourmaline Bio (TRML) has been catching investor attention recently, even without a specific event driving the headlines. Sometimes, stocks start to move or attract renewed interest for reasons that ...
Novartis has bulked up its cardiology pipeline with a $1.4 billion takeover of Tourmaline Bio and its phase 3-ready drug for ...
Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ...
Novartis said it would buy Tourmaline Bio in a deal worth $1.4 billion, building out its pipeline with a promising heart ...
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease ...
Novartis (NVS) to acquire Tourmaline Bio (TRML) for $48.00 per share in cash, or a total equity value of approximately $1.4 ...
Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and ...
Tourmaline Oil (TSE:TOU – Free Report) had its target price lowered by CIBC from C$80.00 to C$72.50 in a research report sent to investors on Thursday morning,BayStreet.CA reports. Other research ...
Tourmaline Oil (TSE:TOU – Free Report) had its price objective lowered by CIBC from C$77.50 to C$75.00 in a research note released on Friday morning,BayStreet.CA reports. A number of other analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback